Brand new immunotherapy combination shows promise for patients with advanced melanoma

Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior treatment with an immune gate inhibitor, and fewer than anticipated undesirable events, according to results from a stage Ib clinical trial presented here at the AACR Annual Meeting 2017, April 1-5. Related Posts:Radioimmunotherapy, Gemcitabine combination shows early…New nanopharmaceutical may help overcome resistance to…Tucatinib (ONT-380) progressing in pivotal demo against…Analysis tackles liver transplant failureCTCA at Western Regional Medical Center advances combinationThe post Brand new immunotherapy combination shows promise for patients with advanced melanoma appeared first on My Irritable Bowel Syndrome Story.
Source: My Irritable Bowel Syndrome Story - Category: Gastroenterology Authors: Tags: IBS News Source Type: blogs